A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy

A Phase 1 Study of MGD020 as a Single Agent or in Combination With MGD014 in Persons With HIV-1 on Antiretroviral Therapy

Study CP-MGD020-01 is a phase 1, open-label, dose-escalation, and multi-dose expansion study of MGD020 as a single agent or in combination with MGD014 in persons with HIV-1 (PWH) on antiretroviral therapy (ART). The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and pharmacodynamics (PD) of the study drugs. The study consists of 3 parts (Part 1A, Part 1B, and Part 2). The participant's standard of care ART regimen is continued throughout the study period.

MGD020 is a bispecific DART® molecule that binds CD3 and gp41 subunit of HIV-1 envelope. MGD014 is a bispecific DART® molecule that binds CD3 and gp120 subunit of HIV-1 envelope. These DART molecules redirect CD3+ T lymphocytes to kill HIV-1-infected CD4+ T cells.

Part 1A evaluates groups of participants given a single dose of MGD020. A 2-week safety period is observed prior to escalation to the next dose level. Dose escalation continues until either the maximum tolerated dose (MTD) or maximum administered dose (MAD) is determined.

Part 1B begins after the end of Part 1A. Part 1B evaluates groups of participants given a single dose of the MGD020 MTD or MAD from Part 1A and a fixed dose of of MGD014. The first group will be treated with a single dose of MGD020, at a dose determined to be one dose lower than the single-agent MTD/MAD from Part 1A, and a single 300 mcg/kg dose of MGD014. Dose escalation proceeds until either the MTD or MAD is determined.

Part 2 begins after the end of Part 1B. Part 2 is a multi-dose expansion group. Each participant will receive the MTD or MAD of MGD020 from Part 1B and a fixed dose of MGD014 from Part 1B, administered every 2 weeks (Q2W) for 3 combination doses over 4 weeks. Up to 6 participants may be enrolled in Part 2.

Study Overview

• Status: Completed
• Conditions: Human Immunodeficiency Virus I Infection; Immunodeficiency Virus Type 1, Human; Human Immunodeficiency Virus Type 1
• Intervention / Treatment: Biological: MGD020; Biological: MGD014

• Study Type: Interventional
• Enrollment (Actual): 17
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • New York
    • New York, New York, United States, 10029
      • Icahn School of Medicine at Mt. Sinai
  • North Carolina
    • Chapel Hill, North Carolina, United States, 27599
      • UNC Hospital - Chapel Hill
  • Ohio
    • Cleveland, Ohio, United States, 44106
      • Case Western Reserve University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Aged ≥ 18 years and ≤ 70 years of age and able to provide informed consent
• HIV-1 infection documented by rapid HIV test or HIV enzyme or chemiluminescence immunoassay and confirmed by a different second test.

• Plasma HIV-1 RNA viral load

  • < 50 copies/mL at 2 time points within 24 months prior to screening (1 time point within 12 months prior to screening), and
  • < 50 copies/mL at screening, and
  • Not ≥ 50 copies/mL on 2 consecutive time points within 24 months nor > 1000 copies/mL at any time within 6 months prior to screening
• On continuous antiretroviral therapy (ART) for at least 24 months prior to screening and must continue ART throughout the study.
• CD4 cell count > 350 cells/mm3 at screening
• Acceptable laboratory values related to bone marrow, kidney and liver function.
• Individuals of childbearing potential must agree to use highly effective forms of contraception throughout the study through 6 months after the last dose of MGD014.

Exclusion Criteria:

• History of any HIV-1 vaccine or HIV-1 immunotherapy, except MGD014 or MGD020, within 6 months prior to screening.
• History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient.
• Active viral, bacterial, or systemic fungal infection requiring intravenous antibiotic, antiviral, or antifungal treatment within 7 days prior to the initiation of study drug.
• Active coronavirus disease 19 (COVID-19)/severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
• Participation in another investigational clinical research study within 60 days prior to screening.
• History of virologic failure on an ART regimen containing FDA-approved HIV-1 entry inhibitors (maraviroc, enfuvirtide, and/or ibalizumab). Virologic failure is defined as a confirmed plasma HIV-1 RNA ≥ 150 copies/mL following assessment of drug adherence, repeat HIV-1 RNA testing with continued treatment, and/or resistance testing

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

9

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Part 1A: Dose level 1; Single dose MGD020	Biological: MGD020; MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.
Experimental: Part 1A: Dose level 2; Single dose MGD020	Biological: MGD020; MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.
Experimental: Part 1A: Dose level 3; Single dose MGD020	Biological: MGD020; MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.
Experimental: Part 1A: Dose level 4; Single dose MGD020	Biological: MGD020; MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.
Experimental: Part 1A: Dose level 5; Single dose MGD020	Biological: MGD020; MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.
Experimental: Part 1A: Dose level 6; Single dose MGD020	Biological: MGD020; MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.
Experimental: Part 1B: MTD/MAD -1 MGD020 and MGD014; Single dose MGD020 and MGD014	Biological: MGD020; MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.; Biological: MGD014; MGD014 is a bispecific DART molecule that binds CD3 and gp120 subunit of HIV-1 envelope.
Experimental: Part 1B: MTD/MAD MGD020 and MGD014; Single dose MGD020 and MGD014	Biological: MGD020; MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.; Biological: MGD014; MGD014 is a bispecific DART molecule that binds CD3 and gp120 subunit of HIV-1 envelope.
Experimental: Part 2: MGD020 and MGD014; Multiple doses of MGD020 and MGD014	Biological: MGD020; MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.; Biological: MGD014; MGD014 is a bispecific DART molecule that binds CD3 and gp120 subunit of HIV-1 envelope.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number and Types of Adverse Events (AEs), Including Serious Adverse Events (SAEs), and AEs Leading to Treatment Discontinuation in Participants Receiving MGD020 Alone in Part 1A	Observation of side effects determines the highest safe dose for further study	Throughout the study, up to 43 days
Number and Types of AEs, Including SAEs, and AEs Leading to Treatment Discontinuation in Participants Receiving MGD020 and MGD014 in Part 1B.	Observation of side effects determines the highest safe dose for further study	Throughout the study, up to 43 days
Number and Types of AEs, Including SAEs, and AEs Leading to Treatment Discontinuation in Participants Receiving MGD020 and MGD014 in Part 2.	Observation of side effects determines the highest safe dose for further study	Throughout the study, up to 81 days.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean Maximum Concentration of MGD020	The highest concentration of MGD020 at the end of the infusion	Throughout the study, up to 43 days for Parts 1A and 1B, and up to 78 days for Part 2
Mean Maximum Concentration of MGD014	The highest concentration of MGD014 at the end of the infusion (Cmax).	Throughout the study, up to 43 days for Part 1B, and up to 78 days for Part 2
Mean Time to Maximal Concentration of MGD020	The amount of time required to get maximum concentration of MGD020	Throughout the study, up to 43 days for Parts 1A and 1B, and up to 78 days for Part 2
Mean Time to Maximal Concentration of MGD014	The amount of time required to get maximum concentration of MGD014	Throughout the study, up to 43 days for Part 1B, and up to 78 days for Part 2
Mean Area Under the Concentration-time Curve (AUC) of MGD020	Total body exposure to MGD020	Throughout the study, up to 43 days for Parts 1A and 1B, and up to 78 days for Part 2
Mean AUC of MGD014	Total body exposure to MGD014	Throughout the study, up to 43 days for Parts 1B, and up to 78 days for Part 2
Mean Half-life of MGD020	The amount of time needed for the body to clear half of the dose of MGD020	Throughout the study, up to 43 days for Parts 1A and 1B, and up to 78 days for Part 2
Mean Half-life of MGD014	The amount of time needed for the body to clear half of the dose of MGD014	Throughout the study, up to 43 days for Parts 1B, and up to 78 days for Part 2
Mean Volume of Distribution at Steady State (Vss) of MGD020	This parameter measures how much of the drug remains in the bloodstream or is distributed to body tissues.	Throughout the study, up to 78 days for Part 2
Mean Volume of Distribution at Steady State of MGD014	This parameter measures how much of the drug remains in the bloodstream or is distributed to body tissues.	Throughout the study, up to 78 days for Part 2
Mean Clearance of MGD020	Total body clearance of the drug from plasma of MGD020	Throughout the study, up to 43 days for Parts 1A and 1B, and up to 78 days for Part 2
Mean Clearance of MGD014	Total body clearance of the drug from plasma of MGD014	Throughout the study, up to 43 days for Parts 1B, and up to 78 days for Part 2
Number of Participants With Elevations in Serum Cytokine Levels of IFN-γ, IL-2, IL-5, IL-6, IL-10, or TNF-α		Throughout the study, up to 43 days for Parts 1A and 1B, and up to 78 days for Part 2.
Anti-drug Antibody Formation to MGD020	Number of patients who develop antibodies against MDG020	Throughout the study, up to 43 days for Parts 1A and 1B, and up to 78 days for Part 2
Anti-drug Antibody Formation to MGD014	Number of patients who develop antibodies against MDG014	Throughout the study, up to 43 days for Parts 1B, and up to 78 days for Part 2

Collaborators and Investigators

• Sponsor: MacroGenics
• Collaborators: National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH); Department of Health and Human Services
• Investigators: Study Director: Pepi Pencheva, MD, MacroGenics

Study record dates

Study Major Dates

• Study Start (Actual): September 26, 2022
• Primary Completion (Actual): May 29, 2024
• Study Completion (Actual): May 29, 2024

Study Registration Dates

• First Submitted: February 18, 2022
• First Submitted That Met QC Criteria: February 18, 2022
• First Posted (Actual): March 2, 2022

Study Record Updates

• Last Update Posted (Actual): March 28, 2025
• Last Update Submitted That Met QC Criteria: March 26, 2025
• Last Verified: March 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Blood-Borne Infections; Urogenital Diseases; Genital Diseases; Immune System Diseases; Infections; RNA Virus Infections; Virus Diseases; Communicable Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; Slow Virus Diseases; HIV Infections; Acquired Immunodeficiency Syndrome; Immunologic Deficiency Syndromes
• Other Study ID Numbers: CP-MGD020-01; 272201500032C-P00008-9999-1 (U.S. NIH Grant/Contract)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No